Drug industry reacts to Oxfam’s allegations of tax-dodging

By |september 19th, 2018|Big pharma, EFPIA, News, tax avoidance|

Four of the world’s biggest pharma companies appear to hide their profits in tax havens, according to a report published by Oxfam on Tuesday (18 September). Businesses said they are in the clear.

Komentarji so izklopljeni za Drug industry reacts to Oxfam’s allegations of tax-dodging

EFPIA President: Next EU Commission should prioritise competitiveness in pharma innovation

By |julij 3rd, 2018|Big pharma, drug innovation, drug pricing, EFPIA, generic drugs, intellectual property rights, News, Orphan drugs, pharmaceutical companies, SPC manufacturing waiver|

The next European Commission should focus on the bloc’s role in the global context of innovation, as China is “decisive” about creating a reliable framework for intellectual property and connecting biotech start-ups and digital companies, EFPIA’s President Stefan Oschmann told EURACTIV.com in an interview.  

Komentarji so izklopljeni za EFPIA President: Next EU Commission should prioritise competitiveness in pharma innovation

Health care risks being forgotten in Brexit talks, industry warns

By |februar 22nd, 2018|Big pharma, Brexit, European Medicines Agency, News, patients, public health|

Health risks being forgotten in Brexit negotiations, potentially delaying the availability of new medicines and imposing large costs on manufacturers, public health leaders have warned.

Komentarji so izklopljeni za Health care risks being forgotten in Brexit talks, industry warns

Drugs incentives have saved lives in Europe [Sponsored]

By |december 12th, 2017|Big pharma, drug innovation, incentives, Innovation, News, pharma companies|

Without strong incentives to spur continued investment in medical innovation, we cannot hope to ensure the sustainability of European healthcare systems and fulfil the promise of our great union, writes Jan Fischer.

Komentarji so izklopljeni za Drugs incentives have saved lives in Europe [Sponsored]

Pharma boss: Targeting drugs won’t make healthcare systems more sustainable

By |oktober 10th, 2017|Big pharma, EFPIA, European Health Forum Gastein, Health and Pharma, medicine, News, pharmaceuticals|

“Salami-slicing” the cost of medicines, which represent almost one-fifth of health system budgets and are subject to rigorous value assessments, won’t make healthcare systems more sustainable in the future, Nathalie Moll told EURACTIV.com in an interview.

Komentarji so izklopljeni za Pharma boss: Targeting drugs won’t make healthcare systems more sustainable

Drugs firms call for phased transition of regulation after Brexit

By |april 27th, 2017|Big pharma, European Medicines Agency, News, pharmaceutical companies|

Pharmaceutical companies called on Thursday (27 April) for a phased transition in drug regulation after Britain leaves the European Union, in order to avoid supply disruption and protect public health.

Komentarji so izklopljeni za Drugs firms call for phased transition of regulation after Brexit